PT  - JOURNAL ARTICLE
AU  - Kinuya, Seigo
AU  - Kawashima, Atsuhiro
AU  - Yokoyama, Kunihiko
AU  - Koshida, Kiyoshi
AU  - Konishi, Shota
AU  - Watanabe, Naoto
AU  - Shuke, Noriyuki
AU  - Bunko, Hisashi
AU  - Michigishi, Takatoshi
AU  - Tonami, Norihisa
TI  - Cooperative Effect of Radioimmunotherapy and Antiangiogenic Therapy with Thalidomide in Human Cancer Xenografts
DP  - 2002 Aug 01
TA  - Journal of Nuclear Medicine
PG  - 1084--1089
VI  - 43
IP  - 8
4099  - http://jnm.snmjournals.org/content/43/8/1084.short
4100  - http://jnm.snmjournals.org/content/43/8/1084.full
SO  - J Nucl Med2002 Aug 01; 43
AB  - Antiangiogenic therapy may prolong the dormancy of cancer lesions. Moreover, radioimmunotherapy (RIT) may eradicate this population of cells. This study dealt with determining the benefits associated with the combined usefulness of these 2 therapies with respect to inhibition of tumor growth. Methods: Antiangiogenic therapy using oral thalidomide (daily dose, 200 mg/kg) and RIT involving a single intravenous injection (4.63 MBq 131I-A7, an IgG1 murine monoclonal antibody) were conducted in mice bearing LS180 human colon cancer xenografts. RIT with an irrelevant IgG1, HPMS-1, was also performed as a control. Antiangiogenesis of thalidomide was investigated by immunohistochemical analysis of tumor sections. Results: Antiangiogenic therapy and RIT with 131I-A7 significantly suppressed the growth of xenografts. This combination produced more efficient tumor growth inhibition than did the monotherapy (P < 0.005). RIT using 131I-HPMS-1 was far less effective than 131I-A7, even when combined with thalidomide administration. Immunohistochemistry revealed a decrease in the microvessel number within tumors treated with thalidomide (P < 0.0001). Combined therapy further reduced the microvessel number (P < 0.01 vs. thalidomide monotherapy). Conclusion: The combination of RIT and thalidomide antiangiogenic therapy produces a better response of tumors than does monotherapy. Acting in concert, antiangiogenic therapy may prolong the dormancy of cancer lesions and RIT may eradicate this population of cells.